Medicina Legal, Psiquiatría y Patología
Department
Javier
Rejas Gutiérrez
Publications by the researcher in collaboration with Javier Rejas Gutiérrez (14)
2015
-
Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors
Annals of General Psychiatry, Vol. 14, Núm. 1
-
Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice
Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340
2013
-
A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain
Actas Espanolas de Psiquiatria, Vol. 41, Núm. 3, pp. 164-174
-
A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs
Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26
-
Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain
Social Psychiatry and Psychiatric Epidemiology, Vol. 48, Núm. 6, pp. 985-996
2012
-
Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study
European Psychiatry, Vol. 27, Núm. 4, pp. 267-274
-
Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain
ClinicoEconomics and Outcomes Research, Vol. 4, Núm. 1, pp. 157-168
2011
-
Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use
European Addiction Research, Vol. 17, Núm. 5, pp. 262-270
-
Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study
European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875
2010
-
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort
Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109
-
Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study
Journal of Clinical Psychiatry, Vol. 71, Núm. 3, pp. 280-286
2008
-
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study
Schizophrenia Research, Vol. 104, Núm. 1-3, pp. 1-12
-
Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study
Schizophrenia Research, Vol. 99, Núm. 1-3, pp. 23-28
2007
-
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study
Schizophrenia Research, Vol. 90, Núm. 1-3, pp. 162-173